Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Octagon Capital Advisors LP

Q2 2024 · 13F-HR

Octagon Capital Advisors LPholdings as filed

Filed 2024-08-14 · accession 0001839435-24-000005

$636.3M
Reported value
46
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$110.5M17.4%2,880,880CommonSOLE
252828108DNTHDIANTHUS THERAPEUTICS INC$45.2M7.10%1,746,667CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$44.8M7.04%1,140,060CommonSOLE
457669307INSMINSMED INC$43.6M6.85%650,216CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$41.7M6.55%1,180,798CommonSOLE
04272N102AVBPARRIVENT BIOPHARMA INC$33.5M5.26%1,803,304CommonSOLE
925050106VRNAVERONA PHARMA PLC$27.4M4.31%1,895,200CommonSOLE
21833P301CRBPCORBUS PHARMACEUTICALS HLDGS$22.1M3.47%488,000CommonSOLE
152309100CNTACENTESSA PHARMACEUTICALS PLC$21.2M3.33%2,345,075CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$17.5M2.75%690,000CommonSOLE
457669307INSMINSMED INC$16.8M2.63%250,000CALLSOLE
67576A100OCULOCULAR THERAPEUTIX INC$16.6M2.61%2,425,000CommonSOLE
46489V302CATXPERSPECTIVE THERAPEUTICS INC$15.8M2.48%1,580,249CommonSOLE
60255C885BRD1EURMIND MEDICINE MINDMED INC$15.5M2.44%2,153,000CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$13.4M2.11%350,000CALLSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$10.8M1.69%260,000CommonSOLE
877619106TSHATAYSHA GENE THERAPIES INC$10.2M1.61%4,572,222CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$9.5M1.50%1,093,503CommonSOLE
880881107430TERNS PHARMACEUTICALS INC$9.3M1.46%1,364,400CommonSOLE
38341P102GOSSGOSSAMER BIO INC$8.3M1.30%9,187,883CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$8.1M1.27%620,000CommonSOLE
87990A106TNYATENAYA THERAPEUTICS INC$8.0M1.26%2,576,200CommonSOLE
75915K309RGLSREGULUS THERAPEUTICS INC$7.6M1.20%4,263,701CommonSOLE
019818103ALLOVIR INC$7.1M1.11%9,800,000CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$7.0M1.10%600,000CommonSOLE
037326105ANTXAN2 THERAPEUTICS INC$6.9M1.09%3,220,263CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$6.6M1.04%283,372CommonSOLE
471871202JSPRJASPER THERAPEUTICS INC$6.5M1.03%287,500CommonSOLE
713317105PEPGPEPGEN INC$6.0M0.94%376,117CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$5.5M0.87%2,391,114CommonSOLE
23256X100CYBIN INC$5.0M0.79%18,604,650CommonSOLE
15673T100IPSCCENTURY THERAPEUTICS INC$3.4M0.53%1,333,650CommonSOLE
75974E103RENEO PHARMACEUTICALS INC$3.4M0.53%2,250,000CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$3.3M0.53%176,000CommonSOLE
G4444H101BBOTHELIX ACQUISITION CORP II$2.6M0.40%250,000CommonSOLE
73730P108PSTXUSDPOSEIDA THERAPEUTICS INC$2.1M0.34%736,000CommonSOLE
28623U101ELEVATION ONCOLOGY INC$2.0M0.32%747,000CommonSOLE
59045L106MERSANA THERAPEUTICS INC$2.0M0.31%992,000CommonSOLE
03589W102ANNXANNEXON INC$2.0M0.31%400,000CommonSOLE
31189P102FATEFATE THERAPEUTICS INC$1.7M0.27%520,800CommonSOLE
65487U108NKTXNKARTA INC$1.4M0.22%240,000CommonSOLE
67080N101NUVBNUVATION BIO INC$1.3M0.20%431,600CommonSOLE
007002108TORCEURADICET BIO INC$929,0370.15%767,799CommonSOLE
75382E109RAPT THERAPEUTICS INC$890,6000.14%292,000CommonSOLE
008064107AEROVATE THERAPEUTICS INC$772,6300.12%465,440CommonSOLE
05280R100AUTLAUTOLUS THERAPEUTICS PLC$612,4800.10%176,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.